Infantile hemangioma (IH), the most common tumor of infancy, is characterized by an initial
proliferation during infancy followed by spontaneous involution over the next 5–10 years …

Propranolol, a nonselective β-adrenergic receptor (ADRB) antagonist, is the first-line therapy
for severe infantile hemangiomas (IH). Since the incidental discovery of propranolol efficacy …

As the most common benign vascular tumor in infants, infantile hemangioma (IH) is
characterized by rapid growth and vasculogenesis early in infancy, followed by spontaneous …

Propranolol has been widely used in treating infantile hemangiomas (IHs). But recurrence of
IHs was found in some cases on cessation of propranolol treatment. The other is that …

Background Propranolol, a non-selective blocker of the β-adrenoceptor (AR), is a first-line
treatment for infantile hemangioma (IH). Mast cells have been implicated in the …

Aims The pathogenesis of infantile haemangiomas (IHs) is still far from clear despite the fact
that they are common vascular tumours distinctive for their perinatal presentation, rapid …

Aims The role of the renin–angiotensin system (RAS) in the biology of infantile hemangioma
(IH) represents an emerging paradigm, particularly the involvement of renin, angiotensin …

Aims Cells expressing markers of mast cells, macrophages and dendritic cells have
previously been demonstrated within the interstitium of infantile haemangioma (IH). This …

Vascular anomalies (VAs) include a group of distinct lesions, such as vascular system
congenital malformations, as well as benign and malignant vascular tumors. These lesions …

Infantile haemangioma (IH), the most common vascular tumour of infancy, is comprised of
diverse cell types including endothelial cells, pericytes, fibroblasts and immune cells. IH is …